FDA Approves First New Sunscreen Active Ingredient in 27 Years, Ending Regulatory Freeze

For American consumers, the sunscreen aisle has long felt like a compromise between greasy chemical lotions and chalky mineral pastes. While the rest of the world enjoyed advanced, cosmetically elegant sun protection, the United States remained stuck with active ingredients approved in the 1990s. That decades-long regulatory freeze ended on June 9, 2026, when the U.S. Food and Drug Administration (FDA) officially approved a new sunscreen active ingredient for the first time in 27 years.[1]

The newly approved ingredient is bemotrizinol, frequently referred to by its acronym BEMT or its commercial trade name, Tinosorb S. While novel to the U.S. market, bemotrizinol is not a new or experimental compound. It has been used safely and effectively in Europe, Asia, and Australia for over two decades, earning a reputation as one of the most robust ultraviolet (UV) filters in the global cosmetic industry.[3][4][5]

The FDA's decision adds bemotrizinol to the over-the-counter (OTC) sunscreen monograph, permitting its use in nonprescription sunscreens at concentrations of up to 6 percent. The agency classified the ingredient as "generally recognized as safe and effective" (GRASE) for adults and children as young as six months old. For dermatologists, oncologists, and public health advocates, the approval represents a monumental victory in the fight against skin cancer and premature aging.[1][2][6]

To understand why bemotrizinol is so highly anticipated, it is necessary to examine the mechanics of ultraviolet radiation. The sun emits two primary types of rays that damage the skin: UVB and UVA. UVB rays have shorter wavelengths; they are the primary culprits behind visible sunburns and play a major role in the development of melanoma and non-melanoma skin cancers.[6]

UVA rays, on the other hand, have longer wavelengths that penetrate deeper into the dermis. They are present year-round, can pass through window glass, and are the primary drivers of premature skin aging, wrinkling, and oxidative stress. Crucially, UVA rays also suppress the skin's immune system and contribute significantly to skin cancer risk.[4][6]

Historically, the U.S. market has struggled to provide adequate, cosmetically elegant UVA protection. Chemical sunscreens in the U.S. have relied heavily on avobenzone as the primary UVA filter. While avobenzone is effective at absorbing UVA rays, it is notoriously photounstable. When exposed to sunlight, avobenzone rapidly degrades, losing its protective power exactly when the wearer needs it most. To counteract this, formulators must combine it with stabilizing chemicals, which can make the final product feel heavy or irritating to sensitive skin.[3][4]

Mineral sunscreens, utilizing zinc oxide and titanium dioxide, offer excellent, stable broad-spectrum protection. However, these physical filters work by sitting on top of the skin and reflecting light, which inherently leaves a white, chalky residue—commonly known as a "white cast." This aesthetic drawback makes mineral sunscreens particularly unappealing and impractical for people with darker skin tones, creating a barrier to daily use.[3][4]

Bemotrizinol solves both of these problems simultaneously. It is a broad-spectrum chemical filter, meaning a single ingredient effectively absorbs both UVA and UVB rays. It acts as a microscopic solar sponge, absorbing ultraviolet photons, converting them into harmless heat, and dissipating that energy away from the skin.[2][6]

Unlike avobenzone, bemotrizinol is highly photostable. It does not break down or lose its efficacy when bombarded by UV radiation, allowing it to provide reliable, long-lasting protection for hours without the need for heavy chemical stabilizers. Because it is a chemical filter rather than a physical one, it blends seamlessly into the skin without leaving any white cast, regardless of the user's skin tone.[3][5]

Beyond its performance, bemotrizinol boasts a highly favorable safety profile. In recent years, consumers and regulators have raised concerns about older chemical filters, such as oxybenzone, which have been shown to absorb through the skin and enter the bloodstream. Bemotrizinol is a significantly larger molecule. The FDA's review of decades of safety data confirmed that it has exceptionally low levels of skin absorption, remaining on the surface of the stratum corneum where it belongs.[2][6]

If bemotrizinol is so effective and safe, why did it take 27 years to reach American shelves? The delay stems from a fundamental difference in regulatory frameworks. In Europe and much of the world, sunscreens are regulated as cosmetics. In the United States, the FDA classifies sunscreens as over-the-counter drugs, subjecting them to the same rigorous, time-consuming, and expensive clinical trial requirements as pharmaceutical medications.

For years, the FDA required manufacturers to conduct entirely new, U.S.-based clinical trials to prove the safety of ingredients that had already been used by millions of people globally. The breakthrough came with the passage of the CARES Act and the SAFE Sunscreen Standards Act, which modernized the FDA's OTC monograph process. This updated framework allowed the agency to evaluate real-world safety and efficacy data from Europe and Asia, streamlining the approval pathway without compromising scientific rigor.[2][3]

For cosmetic chemists and skincare brands, the approval of bemotrizinol unlocks entirely new formulation possibilities. Because the ingredient is so efficient, formulators can achieve high SPF and broad-spectrum ratings using a lower total percentage of UV filters. This reduction in active ingredients allows for the creation of lighter, more elegant textures—such as watery gels, sheer serums, and weightless lotions that feel like high-end skincare rather than traditional sunblock.[5][6]

Dermatologists emphasize that the best sunscreen is simply the one a patient is willing to wear every single day. By removing the barriers of greasy textures, eye stinging, and white casts, bemotrizinol has the potential to significantly increase daily sunscreen compliance among American consumers. Increased compliance translates directly to lower rates of sunburn, photoaging, and, ultimately, skin cancer.[2][6]

While the FDA's approval is final, consumers will not see bemotrizinol on store shelves immediately. Skincare brands must now formulate new products, conduct stability testing, and scale up manufacturing—a process that typically takes several months to a year. However, industry experts anticipate a wave of next-generation sunscreens featuring the ingredient to launch ahead of the 2027 summer season.[5]

The introduction of bemotrizinol may also pave the way for further modernization of the U.S. sunscreen market. Advocates and industry leaders are hopeful that the streamlined regulatory process will soon facilitate the approval of other advanced European filters, such as bisoctrizole (Tinosorb M) and drometrizole trisiloxane (Mexoryl XL). For now, the approval of bemotrizinol marks a historic milestone, finally bringing American sun protection out of the 1990s and into the modern era.[1][3][4]